APA (7th ed.) Citation

Ehling, T. J., Klein, M. K., Smith, L., Prescott, D., Haney, S., Looper, J., . . . Farrelly, J. (2022). A prospective, multi‐centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma. Veterinary & Comparative Oncology, 20(1), 293. https://doi.org/10.1111/vco.12776

Chicago Style (17th ed.) Citation

Ehling, Tara Jean, et al. "A Prospective, Multi‐centre, Veterinary Radiation Therapy Oncology Group Study Reveals Potential Efficacy of Toceranib Phosphate (Palladia) as a Primary or Adjuvant Agent in the Treatment of Canine Nasal Carcinoma." Veterinary & Comparative Oncology 20, no. 1 (2022): 293. https://doi.org/10.1111/vco.12776.

MLA (9th ed.) Citation

Ehling, Tara Jean, et al. "A Prospective, Multi‐centre, Veterinary Radiation Therapy Oncology Group Study Reveals Potential Efficacy of Toceranib Phosphate (Palladia) as a Primary or Adjuvant Agent in the Treatment of Canine Nasal Carcinoma." Veterinary & Comparative Oncology, vol. 20, no. 1, 2022, p. 293, https://doi.org/10.1111/vco.12776.